Effects of Glutathione Diminishment on the Immune Responses against Mycobacterium tuberculosis Infection.
Ruoqiong CaoAfsal KolloliRanjeet KumarJames OwensKayvan SasaniniaCharles VaughnMohkam SinghEdward TruongNala KachourAbrianna BeeverWael KhamasSelvakumar SubbianVishwanath VenketaramanPublished in: Applied sciences (Basel, Switzerland) (2021)
Mycobacterium tuberculosis (M. tb) , the causative agent of tuberculosis (TB), continues to be a global health burden. We have reported that patients with marked deficiency in the production of glutathione (GSH) had impaired granulomatous effector responses against M. tb infection, which were restored when supplementing patients with liposomal GSH (lGSH). However, the effects of GSH deficiency in the lung parenchyma in altering granuloma formation and effector responses against M. tb infection remain unexplored. We aim to elucidate the effects of diethyl maleate (DEM)-induced GSH deficiency during an active M. tb infection in an in vivo mouse model. We assessed for total and reduced GSH levels, malondialdehyde (MDA) levels, cytokine profiles, granuloma formation and M. tb burden. DEM administration significantly diminished total and reduced GSH levels in the lungs and plasma and increased MDA levels in infected mice compared to sham-treated controls. DEM treatment was also associated with an increase in IL-6, TNF-α and ill-formed granulomas in infected mice. Furthermore, M. tb survival was significantly increased along with a higher pulmonary and extrapulmonary bacterial load following DEM treatment. Overall, GSH deficiency led to increased oxidative stress, impaired granuloma response, and increased M. tb survival in infected mice. These findings can provide insight into how GSH deficiency can interfere with the control of M. tb infection and avenues for novel therapeutic approaches.
Keyphrases
- mycobacterium tuberculosis
- fluorescent probe
- pulmonary tuberculosis
- oxidative stress
- immune response
- mouse model
- replacement therapy
- global health
- diabetic rats
- clinical trial
- regulatory t cells
- rheumatoid arthritis
- type diabetes
- metabolic syndrome
- breast cancer cells
- cell death
- emergency department
- cell proliferation
- heat shock
- hiv aids
- antiretroviral therapy
- combination therapy
- newly diagnosed
- interstitial lung disease
- toll like receptor
- human immunodeficiency virus
- inflammatory response
- signaling pathway
- ischemia reperfusion injury
- idiopathic pulmonary fibrosis
- free survival